Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 79NIH 3INDUSTRY 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Myasthenia Gravis 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Cladribine × Clear all
NCT06463587 2026-05-22

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3 Recruiting
264 enrolled

Myasthenia Gravis

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Delta-Fly Pharma, Inc.

Phase 3 Terminated
167 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00718549 2018-08-20

A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Hoffmann-La Roche

Phase 3 Completed
128 enrolled 10 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡